Nov 3, 2025 | Press Releases
Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 WeeksSafety Monitoring...
Oct 31, 2025 | Press Releases
King of Prussia, Pennsylvania–(Newsfile Corp. – October 31, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to...
Oct 21, 2025 | Press Releases
Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania–(Newsfile Corp. – October 21, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Sep 23, 2025 | Press Releases
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania–(Newsfile Corp. – September 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Sep 18, 2025 | Press Releases
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 18, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...
Sep 3, 2025 | Press Releases
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – September 3, 2025) – Phio...
